

High-density lipoprotein cholesterol and nuclear factor I A in type 2 diabetes and mild cognitive impairment: biomarkers and mechanistic insights

Jin Zhao¹, Tingying Zhang¹, Yunling Zhu¹, Jian Qin¹, Shumin Cheng², Yunxia Zhou², Li Zhang^{1,3}, Taoli Liu^{1,3*}

¹Traditional Chinese Medicine Department, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China

²Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China

³Shenzhen Key Laboratory of Chinese Medicine Active Substance Screening and Translational Research, the Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China

Submitted: 13 March 2025; **Accepted:** 23 July 2025

Online publication: 6 September 2025

Arch Med Sci

DOI: <https://doi.org/10.5114/aoms/208529>

Copyright © 2025 Termedia & Banach

***Corresponding author:**

Taoli Liu
Shenzhen Key
Laboratory of Chinese
Medicine Active Substance
Screening and
Translational Research
the Seventh Affiliated
Hospital of Sun
Yat-sen University
No. 628 Zhenyuan Road
518107 Shenzhen, China
E-mail:
liutl3@mail2.sysu.edu.cn,
zhouyx65@mail.sysu.edu.cn

Abstract

Introduction: Type 2 diabetes (T2D) and mild cognitive impairment (MCI) are interrelated conditions that significantly impair quality of life. This study aimed to identify a feasible biomarker for assessing T2D-MCI risk and to evaluate a potential therapeutic strategy.

Material and methods: We integrated data from the National Health and Nutrition Examination Survey (NHANES) with Mendelian randomization (MR) to investigate genetic causal relationships between T2D, MCI, and their shared biomarkers. Transcriptomic analysis identified T2D-associated genes. Clinical trials evaluated the short-term effects of modified fasting therapy (MFT) on glucose regulation and cognitive function. Cellular assays and patient samples were used to validate the regulatory roles of key genes in biochemical markers and downstream signaling pathways.

Results: Among 6,356 T2D and 1,138 MCI subjects, vitamin D, high-density lipoprotein cholesterol (HDL-C), globulin, and creatinine were associated with both conditions. MR analysis showed that higher HDL-C levels reduced T2D risk (OR: 0.9059, 95% CI: 0.8666–0.9470) but increased MCI risk (OR = 1.0482, 95% CI: 1.0216–1.0755). Nuclear factor I A (*NFIA*) was identified as a key HDL-C regulator. In a clinical cohort (17 T2D patients and 23 controls), MFT reduced body mass index fasting glucose and HDL-C, increased *NFIA* expression, and improved Montreal Cognitive Assessment scores, especially in T2D-MCI patients. HDL-C rebounded at 6 months. *In vitro*, *NFIA* overexpression increased intracellular HDL-C and suppressed NF-κB signaling, while *NFIA* knockdown reduced APOA1 and APOE.

Conclusions: HDL-C has divergent genetic effects on T2D and MCI. *NFIA* modulates HDL-C and NF-κB activity, supporting metabolic and cognitive improvements. Targeting *NFIA* through MFT may represent a promising strategy for T2D-MCI prevention and treatment.

Key words: type 2 diabetes, mild cognitive impairment, high-density lipoprotein cholesterol, NHANES, Mendelian randomization.

Introduction

Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by persistent hyperglycemia, primarily driven by insulin resistance and β -cell dysfunction, with both genetic and environmental contributors [1]. Its growing prevalence – particularly among older adults – substantially increases the risk of cardiovascular disease, kidney dysfunction, dementia, and other complications, resulting in significant healthcare and economic burdens. For instance, in China, diabetes-related healthcare costs are projected to rise from 250.2 billion yuan in 2020 to 460.4 billion yuan by 2030, an average annual increase of 6.32% [2]. As disease management advances, attention is increasingly turning to previously overlooked comorbidities, including cognitive decline, cancer, and depression [3].

Mild cognitive impairment (MCI), a clinical state between normal aging and dementia, is closely linked to neurodegenerative diseases such as Alzheimer's and Parkinson's [4]. Metabolic abnormalities – such as T2D, prediabetes, and impaired glucose regulation – accelerate cognitive decline through mitochondrial dysfunction, chronic inflammation, vascular damage, and neuronal loss [5–7]. Greater amyloid burden was associated with increased functional impairment, but this relationship was observed only in veterans with T2DM [8]. Emerging research indicates that fasting may enhance insulin sensitivity, promote β -cell regeneration, and improve glycemic control [9, 10]. Animal studies further suggest that fasting supports memory, motor function, and hippocampal neurogenesis, highlighting its potential in treating both T2D and MCI [11].

T2D commonly coexists with dyslipidemia, typically characterized by elevated triglycerides (TG), reduced high-density lipoprotein cholesterol (HDL-C), and increased low-density lipoprotein cholesterol (LDL-C) [12]. HDL-C facilitates reverse cholesterol transport and provides vascular protection through anti-inflammatory, antioxidant, and antithrombotic effects [13]. In T2D, high TG levels enhance cholesteryl ester transfer protein activity, lowering HDL-C further and impairing insulin secretion and glucose uptake [14]. Notably, small HDL particles can cross the blood–brain barrier, suggesting that peripheral HDL-C levels may influence brain function. Higher HDL-C concentrations have been linked to a lower risk of cognitive decline, likely by reducing cerebrovascular inflammation and preserving neuronal activity [15].

Therefore, this study aimed to identify a shared biomarker for assessing the risk of T2D-related cognitive impairment and to evaluate a non-pharmacological intervention for its regulation. We investigated the causal role of HDL-C and its regulatory gene at the metabolic-cognitive interface.

This integrated approach provides novel insights into potential strategies for the prevention and treatment of comorbid T2D and MCI.

Material and methods

Study design

The study was structured in four stages. Initially, disease-associated indicators were identified by comparing individuals with T2D and MCI to healthy controls, using data from the National Health and Nutrition Examination Survey (NHANES). Genetic causality of key indicators was subsequently assessed through Mendelian randomization (MR), supported by transcriptomic analysis. The clinical efficacy of modified fasting therapy (MFT) was then evaluated in a prospective cohort. Finally, functional validation of candidate genes was carried out through cellular experiments.

NHANES data analysis

NHANES datasets from 1999 to 2018 were analyzed to evaluate health and nutritional status. Participants were excluded if aged under 18, missing essential clinical variables, or lacking survival information. For MCI-related analysis, only individuals with valid Digit Symbol Substitution Test (DSST) scores were included (Supplementary Figure S1).

Definitions of T2D and prediabetes

T2D was defined by hemoglobin A_{1c} (HbA_{1c}) levels $\geq 6.5\%$ or current use of glucose-lowering medication. Prediabetes was defined by HbA_{1c} levels ranging from 5.7% to 6.5%. Participants not meeting either criterion were classified as normoglycemic [16, 17].

MCI diagnosis

MCI was defined in individuals aged ≥ 65 years with DSST scores within the lowest quartile during the 1999–2000, 2001–2002, 2011–2012, or 2013–2014 NHANES cycles [18].

Statistical analysis of NHANES

Statistical analyses were conducted using R software (version 4.2.3) with the application of appropriate survey weights. Continuous variables were reported as means $\pm$ standard deviations or medians with interquartile ranges, while categorical variables were expressed as percentages. Group comparisons were performed using χ^2 tests for categorical variables and ANOVA or Kruskal-Wallis tests for continuous variables. Spearman correlation was employed to examine associations. Statistical significance was defined as $p < 0.05$.

Mendelian randomization

A two-sample MR analysis was conducted using single nucleotide polymorphisms (SNPs) from the GWAS Catalog, filtered by genome-wide significance ($p < 5 \times 10^{-8}$), low linkage disequilibrium ($r^2 < 0.05$), and a 10,000 kb window. Alzheimer's GWAS summary statistics were used as a proxy for MCI. SNPs associated with confounders were excluded using LDlink. The inverse-variance weighted (IVW) method was used as the primary analytic approach, complemented by MR-Egger regression, weighted median, and mode-based estimators. Horizontal pleiotropy and heterogeneity were assessed using the MR-Egger intercept, Cochran's Q test, and MR-PRESSO. All analyses were performed using the "TwoSampleMR" and "MR-PRESSO" R packages (Supplementary Table S1).

Transcriptomic analysis

The RNA-seq datasets from peripheral blood samples of patients with type 2 diabetes in the GEO database (GSE151683, GSE19790, GSE23561, GSE41767, and GSE69528; $n = 151$) were analyzed. Differentially expressed genes (DEGs) were identified using the "limma" and "sva" packages, applying thresholds of $|\log_2FC| > 0.3$ and $p < 0.05$. Heatmaps were generated using the "pheatmap" package. Functional enrichment analysis was performed with "clusterProfiler" and "org.Hs.eg.db". HDL-C-related genes were retrieved from the GeneCards database.

Modified fasting therapy

MFT was implemented in three phases: (1) a 1–2-day pre-fasting period with a fruit-only diet; (2) a 5-day fasting phase with ≤ 550 kcal/day and 3 l/day of water or herbal tea; and (3) a structured refeeding phase. Intravenous L-carnitine (2 g, twice daily) was administered to reduce hunger and promote lipid metabolism [19–21].

Patient recruitment and data collection

A total of 27 patients diagnosed with type 2 diabetes were recruited from the Seventh Affiliated Hospital of Sun Yat-sen University (Ethics Approval No. KY-2021-108-01). Informed consent was obtained from all participants. Clinical parameters, laboratory results, and cognitive assessments were collected before and after the intervention. Diabetes diagnoses were established according to standardized clinical criteria [16].

Cognitive assessment

Cognitive function was assessed before and after the intervention using the Montreal Cognitive Assessment (MoCA) and the DSST. MoCA

scores below 26 were interpreted as indicative of cognitive impairment. Higher DSST scores were considered reflective of better cognitive performance [22].

Transcriptome sequencing

Total RNA was extracted using Vazyme reagents, quantified with Nanodrop and Qubit instruments, and assessed for integrity. Sequencing libraries with approximately 300 bp inserts were prepared and sequenced on the Illumina Nova-Seq 6000 platform. Sequence reads were aligned to the human reference genome, and differential expression analysis was conducted using the "DESeq2" package.

Cell culture

HepG2 and 293T cells were maintained in DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C in a 5% CO₂ incubator. SH-SY5Y cells were maintained in DMEM/F12 with the same supplements and conditions. Cells were seeded at 60–80% confluency prior to experimental procedures.

Western blotting

Proteins were extracted, separated by SDS-PAGE, and transferred to PVDF membranes. Immunoblotting was performed using primary antibodies against NFIA, p65, phosphorylated p65 (p-p65), IκBα, phosphorylated IκBα (p-IκBα), and GAPDH (Cell Signaling Technology). Detection was carried out using HRP-conjugated secondary antibodies (ABclonal) and enhanced chemiluminescence reagents (Vazyme).

Quantitative RT-PCR

Complementary DNA was synthesized using the HiScript III RT Kit (Vazyme). Quantitative PCR was performed with SYBR Green Master Mix (Vazyme). Relative gene expression was normalized to GAPDH and calculated using the $2^{-\Delta\Delta Ct}$ method. Primer sequences are provided in Supplementary Table SII.

Detection of intracellular HDL-C

Cells were washed with PBS, lysed via sonication, and analyzed using a commercial HDL-C assay kit (Nanjing Jiancheng) following the manufacturer's protocol.

Nuclear factor I A (NFIA) siRNA and overexpression plasmid transfection

HepG2 and SH-SY5Y cells were transfected with either NFIA-specific siRNA (si-NFIA) or neg-

active control siRNA (si-NC) or a plasmid encoding *NF1A* for overexpression using Lipofectamine 3000 (Invitrogen), following the manufacturer's instructions. Plasmid DNA or siRNA and transfection reagent was diluted in Opti-MEM, incubated for complex formation, and applied to cells. After 6 h, the medium was replaced. Cells were harvested 48 h after transfection for subsequent qPCR and Western blot analysis.

APOE and APOA1 quantification by enzyme-linked immunosorbent assay (ELISA)

Cellular APOE and APOA1 levels were measured using ELISA kits (FineTest). After lysis, samples were centrifuged at $1000 \times g$ for 10 min at 4°C to remove debris. Supernatants (100 μl) and standards were added to antibody-coated 96-well plates and incubated at 37°C for 1.5 h. Following washing, 100 μl of detection antibody was added and incubated for another hour. After additional washes, 100 μl of HRP-conjugated secondary antibody was applied and incubated for 30 min. Then 90 μl of substrate solution was added and incubated in the dark for 10–20 min. Reactions were stopped with 50 μl of stop solution. Absorbance was measured at 450 nm, and concentrations were calculated using standard curves.

Statistical analysis

Data were analyzed using *t*-tests or Mann-Whitney *U* tests for two-group comparisons, and one-way ANOVA or Kruskal-Wallis tests with post hoc analysis for multiple groups. Paired *t*-tests or Wilcoxon signed-rank tests were used for pre- vs. post-treatment comparisons. Statistical significance was defined as $p < 0.05$.

Results

Baseline characteristics

This study included 49,078 participants (23,916 men and 25,169 women), categorized as normal, prediabetic, or T2D based on HbA_{1c} levels and medication use. As summarized in Table I, 66.4% were normal ($n = 32,586$), 20.7% were prediabetic ($n = 10,316$), and 13.0% had T2D ($n = 6,356$). Mean age increased significantly across groups (41.78, 55.67 and 58.86 years; $p < 0.001$). Most participants were non-Hispanic White with a high school education. The prevalence of hypertension, overweight/obesity, and central obesity, as well as mean values of blood pressure, BMI, waist circumference, triglycerides, and HbA_{1c}, all differed significantly among groups ($p < 0.001$).

Cognitive data were available for 5,011 individuals (2,539 women, 2,471 men), of whom 1,138 (22.7%) were classified with MCI and 3,873

(77.3%) as cognitively normal. As shown in Table I, the MCI group was older and had lower educational attainment, consistent with prior studies [23]. HbA_{1c} levels and rates of hypertension and T2D were significantly higher in the MCI group, while BMI and overweight/obesity status showed no significant differences.

Observational analysis of T2D and MCI indicators in NHANES

NHANES examination and laboratory data were analyzed by quartiles (Supplementary Table SIII). Q4 values were used for comparative analysis of T2D and MCI-related biomarkers (Supplementary Table SIV) as well as for subgroup analysis (Supplementary Tables SV–SVIII). Most biomarkers varied significantly across T2D groups ($p < 0.001$), while fewer differences were observed in MCI. Shared indicators are listed in Table II. This disparity likely reflects the systemic nature of T2D – characterized by metabolic dysfunction and multi-organ involvement – whereas MCI is primarily a neurocognitive condition with more localized physiological effects.

Correlation between key biomarkers and T2D or MCI

Indicators showing significant group differences were further analyzed for correlations with T2D and MCI outcomes. As anticipated, glycohemoglobin, fasting glucose, C-peptide, and two-hour plasma glucose were strongly correlated with T2D ($r > 0.55$, $p < 0.01$) (Supplementary Table SIX). Blood urea nitrogen and red cell distribution width also showed positive correlations ($r > 0.4$) (Figure 1 A). In the MCI group, globulin levels were positively associated ($r > 0.4$), whereas vitamin D and creatinine were negatively correlated ($r < -0.3$). These moderate correlations ($r = 0.3$ – 0.5) indicate potential biochemical differences in cognitive impairment, though their clinical significance is limited.

Causal effects of HDL-C on T2D and MCI: Mendelian randomization analysis

Given the established causal role of blood glucose and insulin in T2D, we investigated additional factors potentially influencing both T2D and MCI. Biomarkers significantly correlated with either condition ($|r| > 0.3$, $p < 0.05$), such as direct HDL-C and uric acid, were selected for MR to assess potential causality.

As presented in Table III, IVW MR identified a significant causal link between HDL-C and both outcomes. Genetically higher HDL-C levels were associated with a lower risk of T2D (odds ratio [OR] = 0.9059, 95% CI: 0.8666–0.9470) but a higher risk of MCI (OR = 1.0482, 95% CI: 1.0216–

Table I. Demographic and individual characteristics

Parameter	Normal	Prediabetes	T2D	P-value	Normal	MCI	P-value
	N = 32586, 66.40%	N = 10136, 20.65%	N = 6356, 12.95%		N = 3873, 77.30%	N = 1138, 22.70%	
Sex, n (%)							
Female	17042 (51.5)	5049 (52.2)	3076 (48.2)	< 0.001	2027 (55.1)	512 (54.1)	0.67
Male	15544 (48.5)	5087 (47.8)	3280 (51.8)		1846 (44.9)	626 (45.9)	
T2D (%)							
Normal	–	–	–	–	1859 (51.9)	428 (41.3)	< 0.001
Prediabetes	–	–	–		1218 (30.7)	364 (29.2)	
Type 2 diabetes	–	–	–		796 (17.5)	346 (29.5)	
Age, mean (SD)	41.78 (16.17)	55.67 (15.38)	58.86 (13.83)	< 0.001	69.01 (6.69)	73.19 (7.38)	< 0.001
Race/ethnicity, n (%)							
Mexican American	6165 (8.2)	1702 (8.5)	1333 (9.5)	< 0.001	414 (2.3)	299 (9.0)	< 0.001
Other Hispanic	2522 (5.5)	905 (5.7)	598 (6.1)		215 (2.7)	157 (13.2)	
Non-Hispanic White	15318 (71.2)	3849 (62.4)	2166 (60.5)		2341 (85.3)	333 (55.6)	
Non-Hispanic Black	5769 (8.8)	2706 (15.6)	1635 (15.0)		634 (5.6)	306 (18.4)	
Other	2812 (6.3)	974 (7.7)	624 (8.9)		269 (4.1)	43 (3.9)	
Education level, n (%)							
< High school	8085 (15.5)	3075 (21.1)	2358 (25.5)	< 0.001	802 (15.3)	787 (59.1)	< 0.001
> High school	16655 (60.7)	4554 (51.9)	2571 (49.5)		2072 (59.0)	152 (18.2)	
High school	7819 (23.7)	2496 (26.9)	1418 (25.0)		997 (25.7)	194 (22.3)	
Others	27 (0.1)	10 (0.1)	9 (0.1)		2 (0.0)	4 (0.4)	
Na	0 (0.0)	1 (0.0)	0.0 (0.0)		0 (0.0)	1 (0.0)	
Hypertension, n (%)							
Normal	20645 (63.1)	3419 (35.9)	1080 (17.9)	< 0.001	773 (21.4)	155 (13.4)	< 0.001
Hypertension	11941 (36.9)	6717 (64.1)	5276 (82.1)		3100 (78.6)	983 (86.6)	
Obesity/overweight, n (%)							
Normal	10121 (30.3)	1534 (14.9)	580 (8.0)	< 0.001	774 (20.3)	228 (22.2)	0.472
Overweight	13400 (41.6)	4079 (39.1)	2124 (29.2)		45.5 (44.4)	521 (45.3)	
Obesity	9065 (28.1)	4523 (46.0)	3652 (62.8)		34.5 (35.2)	389 (32.5)	
Central obesity, n (%)							
Normal	17812 (54.0)	3321 (30.1)	1343 (17.6)	< 0.001	1377 (32.6)	417 (33.6)	0.628
Central obesity	14774 (46.0)	6815 (69.9)	5013 (82.4)		2496 (67.4)	721 (66.4)	
SBP [mm Hg]	116.70 [108.70, 127.30]	125.30 [115.30, 137.30]	128.00 [117.30, 141.00]	< 0.001	131.30 [120.00, 145.30]	139.30 [126.00, 155.86]	< 0.001
DBP [mm Hg]	70.70 [64.00, 78.00]	72.70 [64.70, 79.30]	70.70 [62.00, 78.00]	< 0.001	70.70 [62.70, 77.30]	67.30 [59.30, 76.00]	< 0.001
BMI [kg/m²]	26.59 [23.30, 30.65]	29.30 [25.76, 34.00]	31.80 [27.90, 37.14]	< 0.001	27.81 [24.63, 31.60]	27.60 [24.20, 31.53]	0.237
Waist circumference [cm]	93.50 [83.60, 104.20]	102.40 [93.20, 112.30]	110.30 [100.00, 121.50]	< 0.001	100.60 [91.50, 109.77]	100.10 [91.50, 109.50]	0.646
HbA _{1c} (%)	5.20 [5.00, 5.40]	5.80 [5.70, 6.00]	7.00 [6.40, 8.10]	< 0.001	5.60 [5.40, 6.00]	5.80 [5.40, 6.40]	< 0.001

1.0755). These results were consistent across four additional MR methods, reinforcing their reliability (Figures 1 B, C).

MR-Egger analysis revealed significant heterogeneity in HDL-C's effects on T2D ($p = 1.10 \times 10^{-8}$)

and MCI ($p = 0.0367$), prompting the use of a multiplicative random-effects IVW model to account for this variability. Tests for horizontal pleiotropy using MR-Egger ($p > 0.05$) and MR-PRESSO indicated potential pleiotropy but detected no outlier

Table II. Important common differential laboratory characteristics

Terms	Normal	Prediabetes	T2D	P-value	Normal	MCI	P-value
Albumin, urine [μg/ml]	6.70 [4.20, 15.20]	6.90 [4.40, 19.90]	8.30 [6.40, 57.67]	< 0.001	6.50 [4.10, 21.80]	8.90 [6.00, 53.81]	< 0.001
Creatinine, urine [mg/dl]	80.00 [49.00, 207.00]	80.00 [49.00, 192.00]	83.00 [52.00, 172.00]	0.009	74.00 [43.00, 156.00]	80.00 [50.00, 175.00]	0.006
White blood cell count [1000 cells/μl]	9.50 [8.90, 10.60]	9.80 [9.10, 11.00]	10.20 [9.40, 11.40]	< 0.001	8.75 [8.40, 9.20]	9.10 [8.60, 9.44]	< 0.001
Lymphocyte percent (%)	39.60 [37.40, 43.10]	40.80 [38.20, 44.90]	39.30 [36.80, 43.30]	< 0.001	38.10 [35.70, 41.70]	39.20 [36.58, 43.53]	0.008
Lymphocyte number [1000 cells/μl]	2.90 [2.70, 3.30]	3.10 [2.80, 3.50]	3.20 [2.90, 3.60]	< 0.001	2.70 [2.50, 3.10]	2.90 [2.60, 3.30]	< 0.001
Segmented neutrophils number [1000 cells/μl]	6.10 [5.50, 6.90]	6.20 [5.60, 7.10]	6.50 [5.90, 7.30]	< 0.001	5.80 [5.30, 6.60]	6.00 [5.50, 6.80]	0.011
Red blood cell count [million cells/μl]	5.27 [5.14, 5.44]	5.27 [5.15, 5.47]	5.26 [5.13, 5.44]	0.001	5.08 [4.95, 5.25]	5.12 [4.98, 5.35]	0.002
Glycohemoglobin (%)	5.50 [5.50, 5.60]	6.20 [6.10, 6.30]	9.60 [8.80, 10.90]	< 0.001	6.80 [6.40, 7.70]	7.60 [6.80, 8.60]	< 0.001
Mean cell HGB conc. [g/dl]	35.00 [34.80, 35.30]	34.80 [34.60, 35.20]	34.80 [34.60, 35.30]	< 0.001	35.00 [34.80, 35.30]	34.70 [34.46, 35.10]	< 0.001
Red cell distribution width (%)	13.90 [13.60, 14.50]	14.80 [14.30, 15.50]	14.90 [14.50, 15.90]	< 0.001	14.30 [13.90, 15.00]	14.70 [14.30, 15.30]	< 0.001
Mean platelet volume [fl]	9.20 [8.90, 9.60]	9.30 [9.00, 9.80]	9.40 [9.20, 9.90]	< 0.001	9.30 [9.10, 9.60]	9.40 [9.30, 9.60]	< 0.001
Blood lead [μmol/l]	0.14 [0.12, 0.18]	0.15 [0.13, 0.20]	0.14 [0.12, 0.18]	< 0.001	0.18 [0.16, 0.23]	0.23 [0.20, 0.30]	< 0.001
Folate, serum [nmol/l]	52.50 [44.60, 64.10]	62.50 [54.20, 73.60]	36.60 [27.40, 52.80]	< 0.001	66.60 [59.60, 76.43]	60.70 [50.30, 72.86]	0.009
Folate, RBC [nmol/l RBC]	1426.20 [1250.00, 1720.00]	1620.00 [1420.00, 1960.00]	1830.00 [1570.00, 2300.00]	< 0.001	901.50 [690.80, 1680.00]	802.00 [573.93, 1300.00]	< 0.001
Homocysteine [μmol/l]	9.66 [9.50, 9.82]	8.27 [6.91, 9.86]	8.20 [6.71, 9.85]	< 0.001	8.63 [7.33, 11.45]	9.11 [7.64, 14.71]	< 0.001
Cotinine, serum [ng/ml]	216.00 [61.12, 318.00]	88.27 [82.95, 92.81]	169.00 [35.09, 282.52]	< 0.001	87.49 [0.53, 231.00]	192.98 [29.47, 310.30]	< 0.001
Gamma-tocopherol [μmol/l]	7.57 [6.97, 8.46]	8.29 [7.68, 8.94]	8.74 [8.26, 9.25]	< 0.001	8.26 [7.62, 9.05]	8.85 [8.38, 9.39]	< 0.001
Retinol [μmol/l]	2.60 [2.43, 2.89]	2.69 [2.49, 2.99]	2.81 [2.62, 3.24]	< 0.001	2.97 [2.78, 3.31]	2.75 [2.62, 2.97]	< 0.001
Alkaline phosphatase (ALP) [U/l]	88.00 [85.00, 93.00]	92.00 [89.00, 95.00]	95.00 [93.00, 97.00]	< 0.001	91.00 [88.00, 95.00]	99.00 [98.72, 99.00]	< 0.001
Blood urea nitrogen [mmol/l]	6.43 [5.71, 7.14]	7.14 [6.43, 7.85]	7.85 [7.50, 8.57]	< 0.001	7.85 [7.14, 8.45]	8.20 [7.69, 8.60]	< 0.001

Table II. Cont.

Terms	Normal	Prediabetes	T2D	P-value	Normal	MCI	P-value
Gamma glutamyl transferase (GGT) [U/l]	33.00 [9.00, 45.00]	43.00 [36.00, 55.00]	50.00 [42.00, 63.00]	< 0.001	37.00 [31.00, 47.00]	43.00 [36.00, 61.61]	< 0.001
Iron [μmol/l]	21.10 [8.60, 24.70]	18.40 [8.40, 21.30]	17.60 [8.20, 20.60]	< 0.001	165.00 [157.00, 183.00]	177.00 [168.00, 197.00]	< 0.001
Lactate dehydrogenase (LDH) [U/l]	155.00 [98.00, 169.00]	169.00 [160.00, 187.00]	167.00 [157.00, 181.00]	< 0.001	166.00 [158.00, 184.00]	180.00 [169.00, 199.00]	< 0.001
Uric acid [μmol/l]	410.40 [386.60, 446.10]	440.20 [416.40, 475.80]	446.10 [422.30, 487.70]	< 0.001	434.20 [410.40, 469.90]	452.00 [428.30, 493.70]	< 0.001
Creatinine [μmol/l]	90.17 [88.40, 97.24]	97.24 [93.70, 97.24]	98.61 [98.12, 99.01]	< 0.001	97.24 [97.20, 98.12]	79.60 [67.18, 103.43]	< 0.001
Potassium [mmol/l]	4.40 [4.30, 4.51]	4.40 [4.30, 4.60]	4.53 [4.40, 4.70]	< 0.001	4.50 [4.40, 4.70]	4.70 [4.50, 4.80]	< 0.001
Globulin [g/l]	34.00 [33.00, 36.00]	36.00 [34.00, 38.00]	37.00 [36.00, 39.00]	< 0.001	34.00 [33.00, 37.00]	38.00 [36.00, 41.00]	< 0.001
Trans-lycopene [μmol/l]	0.66 [0.59, 0.76]	0.63 [0.56, 0.74]	0.58 [0.51, 0.68]	< 0.001	0.58 [0.53, 0.71]	0.52 [0.46, 0.63]	0.002
Vitamin D [nmol/l]	82.50 [77.70, 89.60]	76.20 [70.60, 83.50]	73.00 [68.20, 80.30]	< 0.001	82.50 [77.70, 89.60]	73.00 [71.81, 80.10]	< 0.001
Direct HDL cholesterol [mmol/l]	1.91 [1.78, 2.15]	1.81 [1.68, 2.02]	1.63 [1.53, 1.81]	< 0.001	1.80 [1.68, 2.02]	1.94 [1.78, 2.15]	0.005

SNPs. Leave-one-out analysis confirmed that the associations were not driven by any single SNP but rather reflected contributions from multiple variants. Supplementary Figure S2 and Supplementary Table SX provide detailed SNP information and MR results for other biomarkers.

Transcriptomic profiling and identification of HDL-C-related targets in T2D

To identify molecular targets linking HDL-C and T2D, transcriptomic analysis was performed using 151 samples from five GEO datasets. Batch effects were corrected before downstream analysis (Supplementary Figures S3 A, B). In total, 552 DEGs were identified in the T2D group compared to non-diabetic (ND) controls, with 232 genes up-regulated and 320 downregulated (Figure 1 D). KEGG analysis of the DEGs revealed significant enrichment in pathways such as mitophagy, PI3K-Akt signaling, autophagy, cholinergic synapse, and apoptosis (Supplementary Figure S3 C). In parallel, GSEA demonstrated that these DEGs were closely associated with Alzheimer's disease (AD) (Figure 1 E), suggesting a potential link between T2D and increased risk of AD.

To further explore HDL-C-related genes implicated in T2D, genes associated with HDL-C (GeneCards relevance score ≥ 1 , Supplementary Table SXI) were cross-referenced with T2D DEGs and SNP-annotated loci. This integrative approach identified one candidate gene, NFIA (Figure 1 F), potentially bridging HDL-C regulation with T2D pathogenesis.

Therapeutic effects of MFT on T2D and MCI

Forty participants (17 with T2D and 23 controls) completed the MFT intervention. Baseline characteristics are provided in Supplementary Table SXII. After MFT, significant reductions were observed in BMI ($p < 0.0001$), fasting blood glucose (FBG; $p < 0.0006$), and HDL-C ($p < 0.0001$), while β -hydroxybutyrate (β -HB) levels rose markedly ($p < 0.0001$) (Figures 2 A–D). FBG decreased more substantially in the T2D group compared to controls ($p = 0.0199$) (Supplementary Figure S4 A). At 3 and 6 months, HDL-C levels rebounded above both baseline and immediate post-fasting levels (Figures 2 E, F). Cognitive function was assessed using the MoCA ($n = 31$) and the DSST ($n = 27$). Baseline MoCA scores were lower in the T2D group than in controls ($p = 0.0248$) (Figure 2 G). Following MFT, MoCA scores improved significantly overall, with the most pronounced gains observed in T2D patients with MCI ($p = 0.0109$) (Figure 2 J). DSST scores also improved in this subgroup ($p = 0.0237$) (Figure 2 I), although group-level changes were not statistically significant (Supplementary




Figure 1. Integrated analysis of molecular correlates and gene signatures in T2D, MCI, and AD. **A** – Correlation heatmap of differential indicators with T2D and MCI. **B, C** – Scatter plots showing the association between HDL-C and the risk of T2D and MCI. **D** – Distribution of upregulated and downregulated genes. **E** – GSEA enrichment plot for the Alzheimer disease-related gene set. **F** – Venn diagram showing the overlapping genes among ND-T2D DEGs (orange), GeneCards (blue), and MR-SNPs (green). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

Figures S4 B, C). These results indicate that T2D is associated with elevated MCI risk, and that MFT can enhance both metabolic and cognitive outcomes, especially in patients with comorbid T2D and MCI.

Expression of NFIA, a key gene identified through prior analyses, was significantly upregulated after MFT ($p = 0.0002$), particularly in participants with T2D ($p = 0.0004$) and MCI ($p = 0.001$), whereas changes in controls did not reach statistical significance ($p = 0.098$) (Figure 2 K, Supplementary Figures S4 D–F).

Transcriptomic analysis of MFT response

Peripheral blood RNA-seq was performed on samples from eleven randomly selected participants (5 T2D and 6 control) before and after MFT. Using thresholds of $|\log_2 FC| > 0.3$ and $p < 0.05$, we identified 447 upregulated and 246 downregulated DEGs after MFT (Figure 3 A, Supplementary Table SXIII), with NFIA among the upregulated genes. KEGG enrichment analysis revealed that upregulated DEGs were involved in pathways related to unsaturated fatty acid biosynthesis, fatty acid metabolism, and PI3K-Akt signaling, suggesting that MFT may improve metabolic function and insulin sensitivity through these molecular pathways (Figure 3 B, Supplementary Figure S5).

Functional role of NFIA in HepG2 and SH-SY5Y cells

The NFIA gene plays a key role in the regulation of HDL-C, which is primarily synthesized in the liver [24]. To investigate its function, we overexpressed NFIA in HepG2 cells. Overexpression was confirmed via qPCR and Western blotting (Supplementary Figures S6 A, B). Intracellular HDL-C levels were significantly higher in NFIA-overexpressing cells compared to controls ($p = 0.0002$; Figure 3 C). Additionally, NFIA overexpression reduced phosphorylation of NF- κ B p65 and I κ B α , indicating inhibition of the NF- κ B signaling pathway (Figures 3 D–F). These findings suggest a potential anti-inflammatory mechanism. At the same time, following NFIA knockdown in HepG2 and SH-SY5Y cells (Supplementary Figures S6 C, D), ELISA results showed decreased levels of APOA1 (HepG2: $p = 0.0228$; SH-SY5Y: $p = 0.0014$) and APOE (HepG2: $p = 0.0097$; SH-SY5Y: $p = 0.0023$) (Figures 3 G–I, Supplementary Figures S6 E, F). These findings suggest that NFIA may play a regulatory role in HDL-C biosynthesis.

Discussion

Mounting evidence indicates a shared pathogenic pathway between T2D and MCI, driven largely by hyperglycemia, chronic inflammation,

Table III. Genetically predicted HDL-C and T2D/MCI risk

Outcome	MR method	Numbers of SNPs	β	SE	OR (95% CI)	P-value for association	P-value for heterogeneity test	P-value for MR-Egger intercept	P-value for MR-PRESSO global test	Outlier
Type 2 diabetes	MR Egger	132	-0.0319	0.0408	0.9686 (0.8941,1.0493)	0.4362	1.105E-08	0.0522	< 0.0003	NA
	Weighted median		-0.0689	0.0294	0.9334 (0.8812,0.9888)	0.0190				
	Inverse variance weighted		-0.0988	0.0226	0.9059 (0.8666,0.9470)	0.0000				
	Simple mode		-0.1435	0.0645	0.8663 (0.7634,0.9832)	0.0279				
	Weighted mode		-0.0726	0.0292	0.9300 (0.8783,0.9847)	0.0141				
Alzheimer's disease	MR Egger	134	0.0550	0.0202	1.0565 (1.0156,1.0991)	0.0072	0.1135	0.7016	0.1363	rs1846692
	Weighted median		0.0677	0.0189	1.0701 (1.0311,1.1105)	0.0003				
	Inverse variance weighted		0.0490	0.0127	1.0502 (1.0244,1.0767)	0.0001				
	Simple mode		0.0334	0.0337	1.0339 (0.9678,1.1045)	0.3238				
	Weighted mode		0.0564	0.0159	1.0580 (1.0255,1.0915)	0.0006				




Figure 2. Analysis of key indicators before and after MFT. **A** – BMI ($n = 40$); **B** – FBG ($n = 40$); **C** – β -HB ($n = 40$); **D** – HDL-C ($n = 34$); **E** – HDL-C levels were followed up for 3 months ($n = 18$); **F** – HDL-C levels were followed up for 3 months ($n = 10$); **G** – Baseline MoCA scores (Ctrl: $n = 15$, T2D: $n = 16$); **H** – MoCA score ($n = 31$); **I** – DSST scores in T2D&MCI group ($n = 8$). Data presented as mean $\pm$ SD. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$




Figure 2. Cont. J – MoCA score changes by group (Ctrl: $n = 15$, T2D: $n = 16$, MCI: $n = 11$, T2D&MCI: $n = 8$); K – NFIA expression in peripheral blood ($n = 40$). Data presented as mean $\pm$ SD. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$

and neuronal dysfunction [25–27]. Hyperglycemia promotes systemic inflammation, contributing to widespread tissue damage, including the brain.

NHANES data revealed significant differences in serum vitamin D, globulin, and HDL-C levels among individuals with T2D, MCI, and healthy controls. MR analysis showed that genetically elevated HDL-C is associated with a lower risk of

T2D but a higher risk of MCI. Vitamin D levels were inversely associated with both conditions. Supplementation may reduce the incidence of T2D and MCI, even in patients with existing diabetes. This protective effect is likely mediated by the regulatory role of vitamin D in insulin signaling, particularly through inhibition of pathways such as NF- κ B and TLR4 [28]. Vitamin D receptors in pan-




Figure 3. Transcriptomic and functional validation analyses related to NFIA. A – Volcano plot of DEGs in peripheral blood before and after MFT; B – KEGG enrichment of up-regulated DEGs. Data presented as mean $\pm$ SD. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$




Figure 3. Cont. **C** – HDL-C levels in *NFIA*-overexpressing (OE-NFIA) HepG2 cells; **D–F** – Western blotting analysis of NF-κB signaling pathway in OE-NFIA HepG2 cells; **G** – APOA1 levels in si-NFIA HepG2 cells; **H** – APOA1 levels in si-NFIA SH-SY5Y cells; **I** – APOE levels in si-NFIA HepG2 cells; **J** – APOE levels in si-NFIA SH-SY5Y cells. Data presented as mean ± SD. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$

creatic β -cells, skeletal muscle, and adipose tissue enhance insulin sensitivity and preserve β -cell function, slowing T2D progression [29]. Additionally, vitamin D supports neuroprotection, calcium balance, antioxidant activity, and anti-inflammatory processes [30]. Clinical studies associate higher serum vitamin D levels in older adults with better cognitive function [31].

An apparent contradiction exists regarding HDL-C. NHANES data suggest that higher HDL-C is protective against MCI, while MR analyses indicate that genetically elevated HDL-C increases MCI risk. This discrepancy stems from methodological differences: MR reflects lifelong genetic exposure and minimizes confounding and reverse causality [32, 33], whereas NHANES offers cross-sectional snapshots influenced by age, lifestyle, and comorbidities [34]. Moreover, HDL composition differs between the central nervous system (CNS) and periphery. CNS HDL includes peripheral APOA1 and glial-derived APOE. The APOE4 isoform, a major genetic risk factor for neurodegeneration, promotes amyloid- β accumulation, tau pathology, and blood-brain barrier disruption [35, 36]. Therefore, if peripheral HDL-C primarily reflects APOA1 rather than APOE, the protective association observed in NHANES remains biologically plausible.

To account for genetic effects driven by *APOE*, *APOE* ϵ 4-related SNPs were excluded in the two-sample MR analysis. Nonetheless, a direct positive causal relationship between HDL-C and MCI was still observed. This may be attributed to the fact that APOE4 protein levels are regulated not only at the transcriptional level by *APOE* ϵ 4 but also through post-transcriptional mechanisms. While genes involved in these regulatory processes may not directly cause MCI, they could influence disease progression by modulating APOE4 expression. In addition, HDL undergoes post-translational modifications that can generate functionally abnormal forms such as oxidized HDL and acetylated HDL [37, 38]. These altered HDL particles may induce endothelial dysfunction and elevate inflammation through multiple pathways, thereby contributing to neuronal injury and cognitive decline.

Conventional lipid-lowering therapies have limited efficacy in elevating HDL-C. Although niacin can increase HDL-C levels, its use is restricted by adverse side effects. As an alternative, we implemented MFT, a non-pharmacological intervention widely used in the management of obesity and diabetes. MFT enhances fatty acid mobilization and ketone body production, providing an alternative energy source – particularly for the brain – during fasting states [39]. Mild hyperketonemia, induced by fasting or ketogenic diets, has been shown to regulate inflammation, oxidative stress [40], glucose metabolism, insulin sensitivity, and synaptic

plasticity [41, 42], thereby improving cognitive and motor function [43, 44]. In our MFT cohort, short-term improvements were observed in FBG, β -HB, and cognitive performance. Although HDL-C levels initially declined after the intervention, they increased significantly at six months, consistent with findings reported by Longo and Frigeri [45, 46].

Genome-wide association and transcriptomic analyses identified *NFIA* as a key regulator of HDL-C metabolism. Following MFT, *NFIA* expression was markedly upregulated in peripheral blood. *NFIA* has been shown to enhance circulating HDL-C [47, 48], suppress pro-inflammatory cytokines [49], and protect against hyperglycemia and weight gain in high-fat diet models [50]. It also plays a role in mitigating T2D and obesity-related metabolic dysfunction [47]. *In vitro*, *NFIA* overexpression elevated HDL-C levels and inhibited classical NF- κ B signaling, suggesting dual roles in lipid regulation and inflammation. These results indicate that MFT may exert its beneficial effects, in part, through *NFIA*-mediated pathways. Given the lack of effective treatments for MCI, MFT offers a safe and promising strategy with therapeutic potential for both metabolic and cognitive disorders.

Despite the novel association we report between *NFIA* expression and MCI in T2D, its immediate clinical translatability is limited. *NFIA* remains a tissue-level transcription factor without validated circulating assays or prospective cohort data supporting its biomarker role. Moreover, the observed relationship between higher HDL-C and increased MCI risk in our cohort likely reflects qualitative HDL dysfunction rather than a true deleterious effect of cholesterol-rich lipoproteins. In T2D, HDL undergoes glycation and oxidative modifications – mediated in part by myeloperoxidase – that impair cholesterol efflux capacity and confer pro-inflammatory properties, potentially exacerbating neuroinflammation and cognitive decline [51, 52]. Thus, future studies should focus on assays of HDL functionality rather than HDL-C levels alone. Finally, although intermittent fasting has garnered considerable interest, large randomized trials demonstrate that its benefits for weight loss and metabolic health are not superior to those achieved by equivalent caloric restriction [53]. However, intermittent fasting may be more feasible over the long term than continuous caloric restriction [54], and Arciero *et al.* have shown that it is more effective at reducing visceral fat [55]. As such, the mechanistic impact of fasting regimens on HDL quality and neuroprotection in diabetic patients warrants rigorous, targeted investigation.

This study has several limitations. First, in the NHANES analysis, the number of participants who completed the DSST cognitive test was limited, resulting in a smaller MCI group compared to the

T2D group. Second, the clinical study of MFT lacked longitudinal cognitive follow-up, which precluded the evaluation of its long-term effects on memory.

In conclusion, we identified HDL-C as an independent factor associated with both T2D and MCI, and observed significant alterations in *NFIA* expression among individuals with T2D. MFT, a non-pharmacological dietary intervention, was found to upregulate *NFIA*, leading to sustained increases in HDL-C, suppression of NF- κ B signaling, and concurrent improvements in glycemic control and cognitive performance – particularly in T2D patients with MCI. These results suggest that *NFIA* and HDL-C may serve as dual biomarkers for early detection of metabolic-cognitive comorbidity. MFT offers a safe, practical approach to modulate this pathway. Further longitudinal studies in diverse populations are warranted to validate these findings and assess the potential of *NFIA*-targeted strategies in personalized prevention and treatment of T2D and MCI.

Acknowledgments

Jin Zhao, Tingying Zhang, Yunling Zhu are co-first authors

Funding

This work was supported by the Traditional Chinese Medicine Bureau of Guangdong Province (no. 20231077); Basic and Applied Basic Research Foundation of Guangdong Province (no.2022A1515220096); Shenzhen Fundamental Research Program (no. JCYJ20230807110417036); Shenzhen Key Laboratory of Chinese Medicine Active substance screening and Translational Research (ZDSYS20220606100801003, No. SKLC-MASSTR202404M).

Ethical approval

Ethics approval was granted by the Ethics Committee of the Seventh Affiliated Hospital, Sun Yat-sen University (KY-2021-108-01).

Conflict of interest

The authors declare no conflict of interest.

References

- Eizirik DL, Pasquali L, Cnop M. Pancreatic beta-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. *Nat Rev Endocrinol* 2020; 16: 349-62.
- Liu J, Liu M, Chai Z, et al. Projected rapid growth in diabetes disease burden and economic burden in China: a spatio-temporal study from 2020 to 2030. *Lancet Reg Health West Pac* 2023; 33: 100700.
- Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. *Nat Rev Endocrinol* 2022; 18: 525-39.
- Baiano C, Barone P, Trojano L, Santangelo G. Prevalence and clinical aspects of mild cognitive impairment in Parkinson's disease: a meta-analysis. *Mov Disord* 2020; 35: 45-54.
- Xue M, Xu W, Ou YN, et al. Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies. *Ageing Res Rev* 2019; 55: 100944.
- Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. *Nat Rev Endocrinol* 2018; 14: 591-604.
- Shen Z, Li ZY, Yu MT, Tan KL, Chen S. Metabolic perspective of astrocyte dysfunction in Alzheimer's disease and type 2 diabetes brains. *Biomed Pharmacother* 2023; 158: 114206.
- Durazo AA, Weigand AJ, Bangen KJ, et al. Type 2 diabetes moderates the association between amyloid and 1-year change in everyday functioning in older veterans. *J Alzheimers Dis* 2024; 97: 219-28.
- Brandhorst S, Levine ME, Wei M, et al. Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. *Nat Commun* 2024; 15: 1309.
- Cheng CW, Villani V, Buono R, et al. Fasting-mimicking diet promotes Ngn3-driven beta-cell regeneration to reverse diabetes. *Cell* 2017; 168: 775-88 e12.
- Brandhorst S, Choi IY, Wei M, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. *Cell Metab* 2015; 22: 86-99.
- Kane JP, Pillinger CR, Goldfine ID, Malloy MJ. Dyslipidemia and diabetes mellitus: role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus. *Curr Opin Pharmacol* 2021; 61: 21-7.
- Poliakova T, Wellington CL. Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia. *Mol Neurodegener* 2023; 18: 86.
- von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein revisited: biological functions and clinical relevance. *Eur Heart J* 2023; 44: 1394-407.
- Vital C, Wellington CL, Calabresi L. HDL and cholesterol handling in the brain. *Cardiovasc Res* 2014; 103: 405-13.
- American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. *Diabetes Care* 2020; 43 (Suppl 1): S14-31.
- Ciardullo S, Perseghin G. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. *Metabolism* 2021; 121: 154752.
- Chen SP, Bhattacharya J, Pershing S. Association of vision loss with cognition in older adults. *JAMA Ophthalmol* 2017; 135: 963-70.
- Virmani MA, Cirulli M. The role of L-carnitine in mitochondria, prevention of metabolic inflexibility and disease initiation. *Int J Mol Sci* 2022; 23: 2717.
- Zhang T, Zhang L, Ke B, et al. L-carnitine ameliorated weight loss in fasting therapy: a propensity score-matched study. *Complement Ther Med* 2019; 44: 162-5.
- Liu T, Ye Z, Feng J, et al. Efficacy and safety of modified fasting therapy for weight loss in 2054 hospitalized patients. *Obesity* 2023; 31: 1514-29.
- Cukierman-Yaffe T, Gerstein HC, Colhoun HM, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. *Lancet Neurol* 2020; 19: 582-90.

23. Lovden M, Fratiglioni L, Glymour MM, Lindenberg U, Tucker-Drob EM. Education and cognitive functioning across the life span. *Psychol Sci Public Interest* 2020; 21: 6-41.
24. Han YH, Onufer EJ, Huang LH, et al. Enterically derived high-density lipoprotein restrains liver injury through the portal vein. *Science* 2021; 373: eabe6729.
25. Little K, Llorian-Salvador M, Scullion S, et al. Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline. *Trends Endocrinol Metab* 2022; 33: 50-71.
26. Dewanjee S, Chakraborty P, Bhattacharya H, et al. Altered glucose metabolism in Alzheimer's disease: role of mitochondrial dysfunction and oxidative stress. *Free Radic Biol Med* 2022; 193: 134-57.
27. Zhang S, Lachance BB, Mattson MP, Jia X. Glucose metabolic crosstalk and regulation in brain function and diseases. *Prog Neurobiol* 2021; 204: 102089.
28. Dong B, Zhou Y, Wang W, et al. Vitamin D receptor activation in liver macrophages ameliorates hepatic inflammation, steatosis, and insulin resistance in mice. *Hepatology* 2020; 71: 1559-74.
29. Pittas AG, Kawahara T, Jorde R, et al. Vitamin D and risk for type 2 diabetes in people with prediabetes: a systematic review and meta-analysis of individual participant data from 3 randomized clinical trials. *Ann Intern Med* 2023; 176: 355-63.
30. Gall Z, Szekely O. Role of vitamin D in cognitive dysfunction: new molecular concepts and discrepancies between animal and human findings. *Nutrients* 2021; 13: 3672.
31. Scarmeas N, Anastasiou CA, Yannakouli M. Nutrition and prevention of cognitive impairment. *Lancet Neurol* 2018; 17: 1006-15.
32. Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. *Nat Rev Cardiol* 2017; 14: 577-90.
33. Davies NM, Holmes MV, Smith GD. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ* 2018; 362: k601.
34. Li Z, Lai J, Wen et al. Higher levels of blood selenium are associated with higher levels of serum lipid profile in US adults with CKD: results from NHANES 2013-2018. *Biol Trace Elem Res* 2023; 201: 5501-11.
35. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 1993; 261: 921-3.
36. Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. *Lancet Neurol* 2021; 20: 68-80.
37. Zhao Y, Wang Y, Zheng H, et al. Hydrogen sulfide upregulates SIRT1 to inhibit ox-HDL-induced endothelial cell damage and mitochondrial dysfunction. *Nitric Oxide* 2024; 152: 78-89.
38. Speer T, Rohrer L, Blyszczuk P, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. *Immunity* 2013; 38: 754-68.
39. Jensen NJ, Wodschow HZ, Nilsson M, Rungby J. Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases. *Int J Mol Sci* 2020; 21: 8767.
40. Veneti S, Grammatikopoulou MG, Kintiraki E, et al. Ketone bodies in diabetes mellitus: friend or foe? *Nutrients* 2023; 15: 4383.
41. Gershuni VM, Yan SL, Medici V. Nutritional ketosis for weight management and reversal of metabolic syndrome. *Curr Nutr Rep* 2018; 7: 97-106.
42. Chung JY, Kim OY, Song J. Role of ketone bodies in diabetes-induced dementia: sirtuins, insulin resistance, synaptic plasticity, mitochondrial dysfunction, and neurotransmitter. *Nutr Rev* 2022; 80: 774-85.
43. Fortier M, Castellano CA, St-Pierre V, et al. A ketogenic drink improves cognition in mild cognitive impairment: results of a 6-month RCT. *Alzheimers Dement* 2021; 17: 543-52.
44. Taylor MK, Sullivan DK, Mahnken JD, et al. Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer's disease. *Alzheimers Dement* 2018; 4: 28-36.
45. Galetti V, Brnic M, Lotin B, Frigeri M. Observational study of lipid profile and c-reactive protein after a seven-day fast. *Nutrients* 2021; 13: 255.
46. Wei M, Brandhorst S, Shlehchi M, et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. *Sci Transl Med* 2017; 9: eaai8700.
47. Hiraike Y, Waki H, Yu J, et al. NFIA co-localizes with PPAR-gamma and transcriptionally controls the brown fat gene program. *Nat Cell Biol* 2017; 19: 1081-92.
48. Zhao JJ, Hu YW, Huang C, et al. Dihydrocapsaicin suppresses proinflammatory cytokines expression by enhancing nuclear factor I A in a NF-kappaB-dependent manner. *Arch Biochem Biophys* 2016; 604: 27-35.
49. Hu YW, Zhao JY, Li SF, et al. RP5-833A20.1/miR-382-5p/NFIA-dependent signal transduction pathway contributes to the regulation of cholesterol homeostasis and inflammatory reaction. *Arterioscler Thromb Vasc Biol* 2015; 35: 87-101.
50. Hiraike Y, Saito K, Oguchi M, et al. NFIA in adipocytes reciprocally regulates mitochondrial and inflammatory gene program to improve glucose homeostasis. *Proc Natl Acad Sci USA* 2023; 120: e2308750120.
51. Ostocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? *Prog Lipid Res* 2012; 51: 314-24.
52. Ganjali S, Dallinga-Thie GM, Simental-Mendia LE, et al. HDL functionality in type 1 diabetes. *Atherosclerosis* 2017; 267: 99-109.
53. Liu D, Huang Y, Huang C, et al. Calorie restriction with or without time-restricted eating in weight loss. *N Engl J Med* 2022; 386: 1495-504.
54. James DL, Hawley NA, Mohr AE, et al. Impact of intermittent fasting and/or caloric restriction on aging-related outcomes in adults: a scoping review of randomized controlled trials. *Nutrients* 2024; 16: 316.
55. Arciero PJ, Poe M, Mohr AE, et al. Intermittent fasting and protein pacing are superior to caloric restriction for weight and visceral fat loss. *Obesity* 2023; 31 Suppl 1: 139-49.